Stay updated with breaking news from Ignacio Melero. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Internationally renowned researchers Gordon Freeman, Ph.D., Thomas Gajewski, M.D., Ph.D., Jason Luke, M.D., Ignacio Melero, M.D., Ph.D., and Anthony Tolcher, M.D., to advise Bright Peak in its mission
More than 50% increase in 6-month PFS versus ipilimumab after progression on first-line anti-PD-1
Based on data from a randomized trial presented at ESMO, the Netherlands Cancer Institute is exploring the possibility of seeking regulatory approval for TIL therapy without pharma involvement.
CatalYm receives International Nonproprietary Name (INN) visugromab for CTL-002 as approved by the World Health Organization CatalYm today announced treatment of the first patients in a series of
Press release content from Business Wire. The AP news staff was not involved in its creation.